Primecap Management Co. CA Decreases Holdings in Health Catalyst, Inc. $HCAT

Primecap Management Co. CA trimmed its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 31.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,369,067 shares of the company’s stock after selling 617,620 shares during the quarter. Primecap Management Co. CA’s holdings in Health Catalyst were worth $3,902,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. AXQ Capital LP purchased a new stake in Health Catalyst during the third quarter valued at $51,000. Vanguard Group Inc. grew its stake in shares of Health Catalyst by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock valued at $12,243,000 after purchasing an additional 119,117 shares during the period. MCF Advisors LLC grew its stake in shares of Health Catalyst by 200.0% during the 3rd quarter. MCF Advisors LLC now owns 75,000 shares of the company’s stock valued at $214,000 after purchasing an additional 50,000 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Health Catalyst during the 3rd quarter valued at about $39,000. Finally, Probity Advisors Inc. lifted its stake in shares of Health Catalyst by 20.5% in the 3rd quarter. Probity Advisors Inc. now owns 45,161 shares of the company’s stock worth $129,000 after purchasing an additional 7,671 shares during the period. Institutional investors own 85.00% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on HCAT shares. Citigroup cut their target price on shares of Health Catalyst from $3.25 to $2.75 and set a “neutral” rating for the company in a research report on Friday, January 9th. Stifel Nicolaus dropped their price target on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating on the stock in a research note on Tuesday, November 11th. UBS Group restated an “outperform” rating on shares of Health Catalyst in a research note on Tuesday, November 11th. William Blair reaffirmed an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.15.

Health Catalyst Stock Down 7.4%

Shares of HCAT stock opened at $1.62 on Friday. The company has a market capitalization of $114.58 million, a price-to-earnings ratio of -1.02 and a beta of 1.73. Health Catalyst, Inc. has a one year low of $1.61 and a one year high of $5.06. The company’s fifty day moving average price is $2.17 and its 200-day moving average price is $2.65. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.88.

Insiders Place Their Bets

In other Health Catalyst news, General Counsel Benjamin Landry sold 27,425 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $2.64, for a total transaction of $72,402.00. Following the sale, the general counsel directly owned 100,000 shares of the company’s stock, valued at $264,000. This trade represents a 21.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Julie Larson-Green sold 47,997 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $2.67, for a total value of $128,151.99. Following the completion of the transaction, the director owned 73,573 shares in the company, valued at $196,439.91. The trade was a 39.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.60% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.